UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present)

Molecules (Basel, Switzerland), 2020-06, Vol.25 (11), p.2666

2020

Volltextzugriff (PDF)

Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations

Molecules (Basel, Switzerland), 2022-02, Vol.27 (5), p.1587

2022

Volltextzugriff (PDF)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

Expert opinion on therapeutic patents, 2021-03, Vol.31 (3), p.223-238

2021

Volltextzugriff (PDF)

Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety

Molecules (Basel, Switzerland), 2021-05, Vol.26 (10), p.3041

2021

Volltextzugriff (PDF)

Editorial: Different cell death modes in cancer treatment

Frontiers in pharmacology, 2023-09, Vol.14, p.1291585-1291585

2023

Volltextzugriff (PDF)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer

International journal of molecular sciences, 2023-10, Vol.24 (19), p.14821

2023

Volltextzugriff (PDF)

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

Molecules (Basel, Switzerland), 2015-10, Vol.20 (10), p.19361-19371

2015

Volltextzugriff (PDF)

A Hemin-Graphene Nanocomposite-Based Aptasensor for Ultrasensitive Colorimetric Quantification of Leukaemia Cells Using Magnetic Enrichment

Biosensors (Basel), 2022-11, Vol.12 (12), p.1070

2022

Volltextzugriff (PDF)

XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer

Biomedicine & pharmacotherapy, 2022-11, Vol.155, p.113537-113537, Article 113537

2022

Volltextzugriff (PDF)

Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors

Molecules (Basel, Switzerland), 2018-06, Vol.23 (7), p.1543

2018

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors

Molecules (Basel, Switzerland), 2019-09, Vol.24 (19), p.3422

2019

Volltextzugriff (PDF)

Synthesis and Structure-Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]pyrimidine Derivatives Bearing Pyrazoline Scaffold

Molecules (Basel, Switzerland), 2017-10, Vol.22 (11), p.1870

2017

Volltextzugriff (PDF)

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors

Molecules (Basel, Switzerland), 2018-06, Vol.23 (7), p.1553

2018

Volltextzugriff (PDF)

Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors

Translational oncology, 2024-01, Vol.39, p.101834-101834, Article 101834

2024

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides

Molecules (Basel, Switzerland), 2017-02, Vol.22 (2), p.310-310

2017

Volltextzugriff (PDF)

Design, Synthesis and Anticancer Activity of 4-Morpholinothieno[3,2-d]pyrimidine Derivatives Bearing Arylmethylene Hydrazine Moiety

Chemical and Pharmaceutical Bulletin, 2012/08/01, Vol.60(8), pp.1037-1045

2012

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

Journal of enzyme inhibition and medicinal chemistry, 2019-01, Vol.34 (1), p.203-217

2019

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3- a ] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors

Frontiers in chemistry, 2022-04, Vol.10, p.815534-815534

2022

Volltextzugriff (PDF)

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

BMC chemistry, 2024-08, Vol.18 (1), p.159-14

2024

Volltextzugriff (PDF)

Synthesis and Biological Evaluation of Novel 4-Morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine Derivatives Bearing Phenylpyridine/ Phenylpyrimidine-Carboxamides

Molecules (Basel, Switzerland), 2016-10, Vol.21 (11), p.1447-1447

2016

Volltextzugriff (PDF)

Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents

European journal of medicinal chemistry, 2012-11, Vol.57, p.162-175

2012

Volltextzugriff (PDF)

Design, Synthesis and Antitumor Activity of Novel Artemisinin Derivatives Using Hybrid Approach

Chemical and Pharmaceutical Bulletin, 2011/08/01, Vol.59(8), pp.984-990

2011

Volltextzugriff (PDF)

Discovery of Triazolo-pyridazine/-pyrimidine Derivatives Bearing Aromatic (Heterocycle)-Coupled Azole Units as Class II c‑Met Inhibitors

ACS omega, 2020-07, Vol.5 (27), p.16482-16490

2020

Volltextzugriff (PDF)

Synthesis and Anticancer Activity of Indolin-2-one Derivatives Bearing the 4-Thiazolidinone Moiety

Archiv der Pharmazie (Weinheim), 2012-01, Vol.345 (1), p.73-80

2012

Volltextzugriff (PDF)

Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides

Medicinal chemistry (Shp-sariqah, United Arab Emirates), 2017-03, Vol.13 (2), p.176

2017

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(117)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present)

Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)

Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety

Editorial: Different cell death modes in cancer treatment

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

A Hemin-Graphene Nanocomposite-Based Aptasensor for Ultrasensitive Colorimetric Quantification of Leukaemia Cells Using Magnetic Enrichment

XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer

Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors

Synthesis and Structure-Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]pyrimidine Derivatives Bearing Pyrazoline Scaffold

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors

Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors

Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides

Design, Synthesis and Anticancer Activity of 4-Morpholinothieno[3,2-d]pyrimidine Derivatives Bearing Arylmethylene Hydrazine Moiety

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3- a ] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R

Synthesis and Biological Evaluation of Novel 4-Morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine Derivatives Bearing Phenylpyridine/ Phenylpyrimidine-Carboxamides

Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents

Design, Synthesis and Antitumor Activity of Novel Artemisinin Derivatives Using Hybrid Approach

Discovery of Triazolo-pyridazine/-pyrimidine Derivatives Bearing Aromatic (Heterocycle)-Coupled Azole Units as Class II c‑Met Inhibitors

Synthesis and Anticancer Activity of Indolin-2-one Derivatives Bearing the 4-Thiazolidinone Moiety

Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides

Suchergebnisse filtern